Essential drug list for cardiovascular diseases in a tertiary health care centre

Varshini Lakshmi Tripura Maddali; Manali Shashidhar; Manjunath G. Narasimhaiah; Harshith Ramesh

doi:10.18203/2319-2003.ijbcp20230397

Authors

Varshini Lakshmi Tripura Maddali Sri Siddhartha Medical College, Tumkur, Karnataka, India
Manali Shashidhar Sri Siddhartha Medical College, Tumkur, Karnataka, India
Manjunath G. Narasimhaiah Department of Pharmacology, Sri Siddhartha Medical College, Tumkur, Karnataka, India
Harshith Ramesh Sri Siddhartha Medical College, Tumkur, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20230397

Keywords:

NLEM, Cardiac drugs, Hospital pharmacy

Abstract

Background: Essential medicines are those that satisfy the priority health care needs of a population. The latest version of NLEM is the 23^rd list, published in September 2022, and contains 384 essential drugs, of which 29 are cardiovascular drugs. The drugs in the list may be huge or small according to the local needs. The objectives of our study are to prepare the essential drug list for cardiovascular disease in a tertiary care hospital and to confirm the essential drug list provided and its availability in the pharmacy.

Methods: We interviewed around 28 consultants from various departments who prescribe these cardiac drugs. The names, doses and dosage forms were noted. The list was verified with the NLEM 2022 and counterchecked in the hospital pharmacy.

Results: Most consultants adhered to NLEM, but an additional 42 drugs were prescribed, amounting to 71 drugs. There are four drugs Warfarin, Rivaroxaban, Furosemide and Torsemide which may be considered for the hospital pharmacy list.

Conclusions: Too many drugs other than those present in the NLEM list are prescribed, which can be reduced by adequately training the consultants to adhere to the prescribed list.

Metrics

Metrics Loading ...

References

Meena DK, Jayanthi M, Ramasamy KTM. Availability of key essential medicines in public health facilities of south indian union territory: one of the crucial components of universal health coverage. Cureus. 2021;13(11):e19419.

Balasubramaniam K. Access to essential medicines as a human right. Polit Med. Available at: https://haiweb.org/encyclopaedia/access-with evidence-development/. Accessed on 20 November 2022.

Kar SS, Pradhan HS, Mohanta GP. Concept of essential medicines and rational use in public health. Indian J Community Med. 2010;35(1):10-3.

Manikandan S, Gitanjali B. National list of essential medicines of India: the way forward. J Postgrad Med. 2012;58(1):68-72.

Dong Z, Tao Q, Sun G. Survey and analysis of the availability and affordability of essential drugs in Hefei based on WHO/HAI standard survey methods. BMC Public Health. 2020;20(1):1405.

Bandameedi R, Mohammed S. A case study on national list of essential medicines (NLEM) in India and WHO EML 2015-Overview. Pharmaceut Reg Affairs. 2015;5:159.

Maiti R, Bhatia V, Padhy BM, Hota D. Essential medicines: an indian perspective. Indian J Community Med. 2015;40(4):223-32.

Piggott T, Nowak A, Brignardello-Petersen R. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO BMJ Open. 2022;12: e053349.

Unnikrishnan R, Mohan V. Diabetes and the WHO model list of essential medicines. Lancet Diab Endocrinol. 2022;10(1):19-20.

National list of essential medicines of India 2011. Available at: https://pharmaceuticals.gov.in/sites/ default/files/NLEM.pdf. Accessed on 20 November 2022.

National List of Essential Medicines of India 2022. Available at: https://main.mohfw.gov.in/sites/ default/files/Notification%20and%20Report%20 on%20National%20List%20of%20Essential%20Medicines%2C%202022. Accessed on 20 November 2022.

National list of essential medicines 2015. Available at: https://www.nhp.gov.in/NHPfiles/NLEM% 2C%202015.pdf. Accessed on 20 November 2022.

Bazargani YT, Ugurlu M, de Boer A, Leufkens HGM, Mantel-Teeuwisse AK. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovasc Disord. 2018;18(1):126.

Satheesh G, Sharma A, Puthean S, Ansil TP, Mishra RS, Unnikrishnan MK. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India. Trop Med Int Health. 2020; 25(12):1467-79.

Dugani SB, Moran AE, Bonow RO, Gaziano TA. Ischemic heart disease: cost-effective acute management and secondary prevention. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, eds. Cardiovascular, Respiratory, and Related Disorders. 3rd ed. Washington (DC): International Bank for Reconstruction and Development publisher; 2017.

Hajjar A, Noujaim C, Mekhael M. Antiarrhythmic drug prescription: socio-economic disparities affect mortality and hospitalization. J Am Coll Cardiol. 2022;79:168.

Sandeep A, Kaur R, Singh TG, Singh M, Satija S, Singh R. Prescribing practices of antihypertensives in a tertiary care hospital: A review. Plant Arch. 2019;19(2):1311-6.

Casu G, Merella P. Diuretic therapy in heart failure - current approaches. Eur Cardiol. 2015;10(1):42-7.

Mehra A, Bhat NK, Sharma SK, Khajuria K. Drug prescribing pattern in patients of myocardial infarction in a tertiary care teaching hospital of North India. Int J Basic Clin Pharmacol. 2020;9:1357-63.

Abbasi MY, Ali MA. Prescribing pattern of drugs in stroke patients: A prospective study. Arch Pharma Pract. 2012;3:283-8.

Coyle K, Coyle D, Blouin J, Lee K, Jabr MF, Tran K, et al. Cost Effectiveness of first-line oral therapies for pulmonary arterial hypertension: a modelling study. Pharmacoeconomics. 2016;34(5):509-20.

Mould-Quevedo JF, Gutiérrez-Ardila MV, Ordóñez Molina JE, Pinsky B, Vargas Zea N. Cost-effectiveness analysis of atorvastatin versus rosuvastatin in primary and secondary cardiovascular prevention populations in Brazil and Columbia. Value Health Reg. 2014;5:48-57.